Global and Regional Trends in Multiple Sclerosis Incidence with Projections to 2030: A Joinpoint Regression Analysis of the GBD Data 2021 by Socio‑Demographic Index and WHO Regions
- 1Student Research Committee, Shiraz University of Medical Sciences, Shiraz
- 2Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz
- 3Research Center for Health Sciences, Institute of Health, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz
Abstract
Background: Multiple sclerosis (MS) constitutes one of the foremost neurological causes of disability among younger and middle‑aged populations. Objective: This study aimed to examine global and regional trends in MS incidence from 1990 to 2021, with projections to 2030, using joinpoint regression and back‑testing validation to ensure evidence‑based scenario selection. Methods: Data were extracted from the Global Burden of Disease (GBD) 2021 study. Joinpoint regression was used to calculate annual percentage changes (APC) and average annual percentage changes (AAPC) for 1990–2021. A retrospective validation (back‑testing) was conducted using data from 1990 to 2015 as the training period to project rates for 2016–2021, comparing predictive accuracy using mean absolute percentage error (MAPE) and root mean square error (RMSE). The method with lower error metrics was selected as the primary projection scenario for 2030, with the alternative retained for sensitivity analysis. Findings: Globally, the age‑standardized incidence rate (ASIR) decreased slightly from 0.77 to 0.75 per 100,000 (1990–2021), while new cases increased by 49.9%. High socio‑demographic index (SDI) (1.66) and EURO (2.57) regions had the highest ASIR in 2021, while low SDI (0.29) and Western Pacific Region (WPRO) (0.15) had the lowest. The back‑testing identified APC as the preferred method in 10 of 12 regions (83.3%), with the lowest MAPE in AFRO (0.05%) and the highest discrepancy in South‑East Asia Region (SEARO) (APC: 0.36% vs AAPC: 5.45%). Global ASIR is projected to decrease slightly to 0.747 by 2030, while SEARO (+12.3%) and low‑middle SDI (+8.2%) regions show the largest increases. Sensitivity analysis confirmed robust projections globally, with trend reversals observed in SEARO and low SDI regions. Conclusion: Global MS incidence is projected to rise in most regions by 2030, particularly in transitioning economies and Southeast Asia. Strengthening diagnostic infrastructure and implementing context‑specific health policies are urgently needed.
Related
- Temporal Trends and Demographic Contributions to Stroke Burden in India, 1990-2023: An Analysis of Global Burden of Disease 2023 Estimates Using Shapley Decomposition and Joinpoint Regression.
- Epidemiological transitions of Visceral Leishmaniasis in G20 countries: A 33-year retrospective joinpoint and demographic decomposition analysis with 20-year ARIMA projections
- Gastric cancer burden from 1990 to 2021, Joinpoint analysis, projections to 2036, and health inequality assessment : Findings from the Global Burden of Disease study 2021
- Divergent suicide mortality trends across South America, 2000–2021: a 12-country joinpoint regression analysis by sex
- Nursing workforce trends in Kazakhstan, 2003–2024: an interrupted time series and joinpoint regression analysis in the context of educational reform
BibTeX
@article{delam2026global,
title = {{Global and Regional Trends in Multiple Sclerosis Incidence with Projections to 2030: A Joinpoint Regression Analysis of the GBD Data 2021 by Socio‑Demographic Index and WHO Regions}},
author = {Hamed Delam and Naeimehossadat Asmarian and Haleh Ghaem},
journal = {Annals of Global Health},
year = {2026},
month = sep,
doi = {10.5334/aogh.5438},
url = {https://doi.org/10.5334/aogh.5438},
note = {CC BY},
}
RIS
TY - JOUR
TI - Global and Regional Trends in Multiple Sclerosis Incidence with Projections to 2030: A Joinpoint Regression Analysis of the GBD Data 2021 by Socio‑Demographic Index and WHO Regions
AU - Hamed Delam
AU - Naeimehossadat Asmarian
AU - Haleh Ghaem
PY - 2026
DA - 2026/09/01
JO - Annals of Global Health
DO - 10.5334/aogh.5438
UR - https://doi.org/10.5334/aogh.5438
AB - Background: Multiple sclerosis (MS) constitutes one of the foremost neurological causes of disability among younger and middle‑aged populations. Objective: This study aimed to examine global and regional trends in MS incidence from 1990 to 2021, with projections to 2030, using joinpoint regression and back‑testing validation to ensure evidence‑based scenario selection. Methods: Data were extracted from the Global Burden of Disease (GBD) 2021 study. Joinpoint regression was used to calculate annual percentage changes (APC) and average annual percentage changes (AAPC) for 1990–2021. A retrospective validation (back‑testing) was conducted using data from 1990 to 2015 as the training period to project rates for 2016–2021, comparing predictive accuracy using mean absolute percentage error (MAPE) and root mean square error (RMSE). The method with lower error metrics was selected as the primary projection scenario for 2030, with the alternative retained for sensitivity analysis. Findings: Globally, the age‑standardized incidence rate (ASIR) decreased slightly from 0.77 to 0.75 per 100,000 (1990–2021), while new cases increased by 49.9%. High socio‑demographic index (SDI) (1.66) and EURO (2.57) regions had the highest ASIR in 2021, while low SDI (0.29) and Western Pacific Region (WPRO) (0.15) had the lowest. The back‑testing identified APC as the preferred method in 10 of 12 regions (83.3%), with the lowest MAPE in AFRO (0.05%) and the highest discrepancy in South‑East Asia Region (SEARO) (APC: 0.36% vs AAPC: 5.45%). Global ASIR is projected to decrease slightly to 0.747 by 2030, while SEARO (+12.3%) and low‑middle SDI (+8.2%) regions show the largest increases. Sensitivity analysis confirmed robust projections globally, with trend reversals observed in SEARO and low SDI regions. Conclusion: Global MS incidence is projected to rise in most regions by 2030, particularly in transitioning economies and Southeast Asia. Strengthening diagnostic infrastructure and implementing context‑specific health policies are urgently needed.
SN - 2214-9996
ER -